NO20091486L - Nye imidazolonderivater, deres fremstilling som medikamenter, farmasoytiske preparater og anvendelse derav som proteinkinaseinhibitorer, saerlig CDC7 - Google Patents

Nye imidazolonderivater, deres fremstilling som medikamenter, farmasoytiske preparater og anvendelse derav som proteinkinaseinhibitorer, saerlig CDC7

Info

Publication number
NO20091486L
NO20091486L NO20091486A NO20091486A NO20091486L NO 20091486 L NO20091486 L NO 20091486L NO 20091486 A NO20091486 A NO 20091486A NO 20091486 A NO20091486 A NO 20091486A NO 20091486 L NO20091486 L NO 20091486L
Authority
NO
Norway
Prior art keywords
alkyl
protein kinase
kinase inhibitors
hal
drugs
Prior art date
Application number
NO20091486A
Other languages
English (en)
Inventor
Vincent Leroy
Eric Bacque
Emmanuel Conseille
Anke Steinmetz
Baptiste Ronan
Jean-Philippe Letallec
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20091486L publication Critical patent/NO20091486L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives forbindelser med formel (1) der: X-Y er NH-C(S), N=C-NR7R8, N=C-SR, N=C-R eller N=C-OR; R og R1 er H eller eventuelt substituert cykloalkyl, alkyl, heterocykloalkyl, aryl eller heteroaryl; R2 er H, Hal eller alkyl; R3 er H, Hal, OH, alkyl eller alkoksy; R4 er H, Hal, CN eller alkyl; R5 er i det vesentlige H, Hal, OH, NR7R8, cykloalkyl, alkyl, alkoksy, heterocykloalkyl, aryl eller heteroaryl, eventuelt substituert; R6 er H, Hal, OH, NI-12, Nhalk,N(alk)2, alkyl eller alkoksy; eller der R7 og R8 slik at en H er eventuelt substituert alk, mens den andre er H eller eventuelt substituert cykloalkyl, alkyl, heterocykloalkyl, heteroaryl eller aryl; eller med R7 og R8 sammen med N danner en eventuelt cyklisk rest som eventuelt inneholder O, S eller N. Det beskrives videre isomerer og salter derav, mer anvendt som medikament og i det vesentlige som proteinkinaseinhibitorer, særlig CDC7. (Henviser til fig. 1).
NO20091486A 2006-10-12 2009-04-16 Nye imidazolonderivater, deres fremstilling som medikamenter, farmasoytiske preparater og anvendelse derav som proteinkinaseinhibitorer, saerlig CDC7 NO20091486L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0608924A FR2907120B1 (fr) 2006-10-12 2006-10-12 Nouveaux derives imidazolones,leur preparation a titre de medicaments,compositions pharmaceutiques,utilisation comme inhibiteurs de proteines kinases notamment cdc7
PCT/FR2007/001651 WO2008046982A2 (fr) 2006-10-12 2007-10-10 Nouveaux derives imidazolones, leur preparation a titre de medicaments, compositions pharmaceutiques, utilisation comme inhibiteurs de proteines kinases notamment cdc7

Publications (1)

Publication Number Publication Date
NO20091486L true NO20091486L (no) 2009-04-16

Family

ID=37964098

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091486A NO20091486L (no) 2006-10-12 2009-04-16 Nye imidazolonderivater, deres fremstilling som medikamenter, farmasoytiske preparater og anvendelse derav som proteinkinaseinhibitorer, saerlig CDC7

Country Status (29)

Country Link
US (1) US8314121B2 (no)
EP (1) EP2094699B1 (no)
JP (1) JP2010505922A (no)
KR (1) KR101552361B1 (no)
CN (1) CN101522678A (no)
AR (1) AR063249A1 (no)
AT (1) ATE517105T1 (no)
AU (1) AU2007311833B2 (no)
BR (1) BRPI0719790A2 (no)
CA (1) CA2660166C (no)
CL (1) CL2007002934A1 (no)
CO (1) CO6160310A2 (no)
CY (1) CY1112066T1 (no)
DK (1) DK2094699T3 (no)
EA (1) EA018496B1 (no)
ES (1) ES2370049T3 (no)
FR (1) FR2907120B1 (no)
HR (1) HRP20110759T1 (no)
IL (1) IL197452A (no)
MA (1) MA30877B1 (no)
MX (1) MX2009003283A (no)
NO (1) NO20091486L (no)
PL (1) PL2094699T3 (no)
PT (1) PT2094699E (no)
RS (1) RS51985B (no)
SI (1) SI2094699T1 (no)
TW (1) TW200821310A (no)
UY (1) UY30642A1 (no)
WO (1) WO2008046982A2 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010122979A1 (ja) 2009-04-20 2010-10-28 Sbiバイオテック株式会社 チアゾリジノン誘導体
EP2454257B1 (en) * 2009-07-15 2013-08-21 AbbVie Inc. Pyrrolopyridine inhibitors of kinases
AU2010326268B2 (en) * 2009-12-04 2016-11-03 Senhwa Biosciences, Inc. Pyrazolopyrimidines and related heterocycles as CK2 inhibitors
CN103003274A (zh) * 2010-04-19 2013-03-27 Abbvie公司 激酶的吡咯并吡啶抑制剂
KR101964479B1 (ko) * 2011-03-31 2019-04-01 카나 바이오사이언스, 인코포레이션 신규 푸라논 유도체
EP3100742B1 (en) 2014-01-31 2020-05-20 Carna Biosciences Inc. Anticancer agent composition comprising a cdc7 inhibitor and a wee1 inhibitor
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
EP4083037A4 (en) * 2019-12-26 2024-01-24 Yonsei Univ Univ Industry Foundation Uif PYRROLIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH BETA-AMYLOID OR TAU PROTEIN CONTAINING THE LATTER

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
EP2295433A3 (en) 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK inhibitors
ES2307040T3 (es) * 2003-08-08 2008-11-16 Pfizer Italia S.R.L. Derivados de pirimidilpirrol activos como inhibidores de cinasa.
CA2561724A1 (en) 2004-04-02 2005-11-03 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
WO2006040049A1 (en) * 2004-10-14 2006-04-20 F. Hoffmann-La Roche Ag Novel azaindole thiazolinones as anti-cancer agents
US7371862B2 (en) * 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them

Also Published As

Publication number Publication date
ATE517105T1 (de) 2011-08-15
CA2660166C (fr) 2015-12-29
CL2007002934A1 (es) 2008-05-30
EA018496B1 (ru) 2013-08-30
FR2907120B1 (fr) 2013-01-11
EA200970364A1 (ru) 2009-10-30
MX2009003283A (es) 2009-04-08
DK2094699T3 (da) 2011-11-07
AU2007311833B2 (en) 2013-05-02
UY30642A1 (es) 2008-05-31
US20090253679A1 (en) 2009-10-08
CY1112066T1 (el) 2015-11-04
IL197452A0 (en) 2009-12-24
ES2370049T3 (es) 2011-12-12
CA2660166A1 (fr) 2008-04-24
US8314121B2 (en) 2012-11-20
FR2907120A1 (fr) 2008-04-18
AR063249A1 (es) 2009-01-14
CO6160310A2 (es) 2010-05-20
EP2094699A2 (fr) 2009-09-02
WO2008046982A3 (fr) 2008-06-19
WO2008046982A2 (fr) 2008-04-24
MA30877B1 (fr) 2009-11-02
KR101552361B1 (ko) 2015-09-10
HRP20110759T1 (hr) 2011-11-30
AU2007311833A1 (en) 2008-04-24
BRPI0719790A2 (pt) 2014-11-25
SI2094699T1 (sl) 2011-11-30
IL197452A (en) 2015-10-29
EP2094699B1 (fr) 2011-07-20
TW200821310A (en) 2008-05-16
PT2094699E (pt) 2011-10-24
JP2010505922A (ja) 2010-02-25
CN101522678A (zh) 2009-09-02
RS51985B (en) 2012-02-29
PL2094699T3 (pl) 2011-12-30
KR20090064571A (ko) 2009-06-19

Similar Documents

Publication Publication Date Title
NO20091486L (no) Nye imidazolonderivater, deres fremstilling som medikamenter, farmasoytiske preparater og anvendelse derav som proteinkinaseinhibitorer, saerlig CDC7
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
NO20063468L (no) Triazolforbindelser og deres anvendelse som metabotrofe glutamatreseptorantagonister
NO20071073L (no) Heterocykel-substituerte cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
NO20082976L (no) Svovelholdige cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
NO20082975L (no) Nye cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
NO20071074L (no) Substituerte cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
MX2009011964A (es) Derivados heterociclicos pirrolo-nitrogenosos, su preparacion y uso farmaceutico.
PE20080318A1 (es) Derivados de diceto-piperazina y piperidina como agentes antivirales
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
NO20062269L (no) Pyridin-karboksylsyrederivater som glucokinasemodulatorer
NO20055977L (no) Nye benzimidazolderivater
NO20085218L (no) Nye pyridinanaloger
NO20060383L (no) Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister
PL378136A1 (pl) Pirymidyny i triazyny hamujące replikacją wirusa HIV
NO20076006L (no) Acetylenderivater
CY1116183T1 (el) Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
PE20090620A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
NO20070157L (no) Substituerte diketopiperaziner som oksytocinantagonister
MX2022000854A (es) Derivados de 2-morfolinopiridina sustituidos como inhibidores de la cinasa atr.
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
MX2009004006A (es) Derivados de indol novedosos, proceso para la preparacion de los mismos y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application